CATX Quote, Financials, Valuation and Earnings

Plus Therapeutics has a net margin of -- compared to Perspective Therapeutics's net margin of --. Perspective Therapeutics's return on equity of -- beat Plus Therapeutics's return on equity of --.

Perspective Therapeutics has a consensus price target of $16.15, signalling upside risk potential of 414.33%. On the other hand Plus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1371.96%. Given that Plus Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Plus Therapeutics is more attractive than Perspective Therapeutics.

Perspective Therapeutics has a beta of 1.129, which suggesting that the stock is 12.894% more volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.519%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Plus Therapeutics quarterly revenues of --. Perspective Therapeutics's net income of -$15.1M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 1.17x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Perspective Therapeutics's net margin of -18.58%. Perspective Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Perspective Therapeutics has a consensus price target of $16.15, signalling upside risk potential of 414.33%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Perspective Therapeutics has higher upside potential than Retractable Technologies, analysts believe Perspective Therapeutics is more attractive than Retractable Technologies.

Perspective Therapeutics has a beta of 1.129, which suggesting that the stock is 12.894% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Perspective Therapeutics's net income of -$15.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.49x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Perspective Therapeutics's net margin of -4291.67%. Perspective Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Perspective Therapeutics has a consensus price target of $16.15, signalling upside risk potential of 414.33%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 476.37%. Given that Catheter Precision has higher upside potential than Perspective Therapeutics, analysts believe Catheter Precision is more attractive than Perspective Therapeutics.

Perspective Therapeutics has a beta of 1.129, which suggesting that the stock is 12.894% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Perspective Therapeutics's net income of -$15.1M is lower than Catheter Precision's net income of -$4.1M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.93x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Perspective Therapeutics's net margin of -17.98%. Perspective Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Perspective Therapeutics has a consensus price target of $16.15, signalling upside risk potential of 414.33%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 458.31%. Given that Xtant Medical Holdings has higher upside potential than Perspective Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Perspective Therapeutics.

Perspective Therapeutics has a beta of 1.129, which suggesting that the stock is 12.894% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Perspective Therapeutics's net income of -$15.1M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.47x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.